Rubin Room 622
Dartmouth Cancer Center
One Medical Center Drive
Lebanon, NH 03756
Patient-derived xenograft mice (PDX) carry tumors that were directly implanted in immunodeficient NSG mice following cancer surgery. The tumors that "take" can be expanded and used to generate groups of mice for testing cancer therapies. PDX is rapidly replacing the use of human cell line xenografts for such studies since they are better at predicting the response to treatment by human tumors. We support all aspects of establishment and utilization of PDX cancer models.
Kerrington D. Smith, MD
Chief, Division of Surgical Oncology
Dr. Smith is a pancreas surgeon, Chief of the Division of Surgical Oncology and Clinical Oncology Group leader for GI oncology at Dartmouth Cancer Center. His translational research lab has developed novel patient-derived xenograft (PDX) models from fine-needle aspiration (FNA) biopsies obtained from primary pancreatic and GI malignancies at the time of the patient’s endoscopic procedure.
Dawn Fischer, BS
Dawn is a level 3 Research Assistant. She has worked with mouse models and human clinical trials since 2001. She has had great success in creating many PDX models.